Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease

被引:14
作者
Droogsma, Erika [1 ]
van Asselt, Dieneke [1 ]
Diekhuis, Marjolein [1 ]
Veeger, Nic [2 ,3 ]
van der Hooft, Cornelis [1 ]
De Deyn, Peter Paul [4 ,5 ,6 ,7 ,8 ]
机构
[1] Med Ctr Leeuwarden, Dept Geriatr Med, NL-8901 BR Leeuwarden, Netherlands
[2] Med Ctr Leeuwarden, Dept Epidemiol, NL-8901 BR Leeuwarden, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Alzheimer Res Ctr, Groningen, Netherlands
[6] Univ Antwerp, Inst Born Bunge, ZNA, Dept Neurol, B-2020 Antwerp, Belgium
[7] Univ Antwerp, Inst Born Bunge, ZNA, Memory Clin, B-2020 Antwerp, Belgium
[8] Univ Antwerp, Inst Born Bunge, Lab Neurochem & Behav, B-2020 Antwerp, Belgium
关键词
Alzheimer's disease; real-life" setting; cholinesterase inhibitors; treatment response; course of cognition; longitudinal study; MINI-MENTAL-STATE; RANDOMIZED CONTROLLED-TRIALS; ACETYLCHOLINESTERASE INHIBITORS; EXTERNAL VALIDITY; GLOBAL PREVALENCE; CLINICAL-PRACTICE; DOUBLE-BLIND; DEMENTIA; GUIDELINES; PREDICTORS;
D O I
10.1017/S1041610215000289
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Some guidelines recommend to discontinue treatment with cholinesterase inhibitors (ChEIs) in patients with Alzheimer's disease (AD) without an initial response to ChEI treatment. Evidence supporting this recommendation, however, is limited. This study aimed to investigate the relation between the initial cognitive response to ChEI treatment and the subsequent long-term course of cognition of AD patients. Methods: The Frisian Alzheimer's Disease Cohort study is a retrospective longitudinal study of 576 community-dwelling AD patients treated with ChEIs in a "real-life" setting at a large memory clinic. A repeated measures analysis using a marginal model (population based averaged model) was applied to investigate whether there is a difference in the subsequent long-term course of cognition (Mini-Mental State Examination (MMSE)) between initial non-responders and responders. Absence of an initial response was defined as a lower MMSE score after the first six months of treatment compared to baseline, a positive response as the same or a higher MMSE score. Results: At baseline, median age was 80 years and the median MMSE score 23. Non-responders showed a slower rate of cognitive decline in the three subsequent years than responders, with a mean annual MMSE decline of 0.9 points versus 1.2 points, respectively (p < 0.0001). Conclusions: Our results suggest that it is not appropriate to discontinue ChEI treatment solely based on the absence of an initial cognitive response.
引用
收藏
页码:1323 / 1333
页数:11
相关论文
共 50 条
  • [31] Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease
    Connelly, PJ
    Prentice, NP
    Fowler, KG
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 20 (07) : 623 - 628
  • [32] Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease
    Xiaoli Pan
    Zhichun Chen
    Guoqiang Fei
    Shumei Pan
    Weiqi Bao
    Shuhua Ren
    Yihui Guan
    Chunjiu Zhong
    Neuroscience Bulletin, 2016, 32 : 591 - 596
  • [33] Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease
    Pan, Xiaoli
    Chen, Zhichun
    Fei, Guoqiang
    Pan, Shumei
    Bao, Weiqi
    Ren, Shuhua
    Guan, Yihui
    Zhong, Chunjiu
    NEUROSCIENCE BULLETIN, 2016, 32 (06) : 591 - 596
  • [34] Long-term Physical Exercise Improves Finger Tapping of Patients with Alzheimer's Disease
    Zhao, Linlin
    Liu, Guanghua
    Zhang, Lingli
    Du, Yuxiang
    Lei, Le
    Zhang, Xiaojing
    Zhao, Yilong
    Shen, Deng
    CURRENT ALZHEIMER RESEARCH, 2021, 18 (14) : 1077 - 1086
  • [35] SHORT-TERM RESPONSE TO CHOLINESTERASE INHIBITORS IN ALZHEIMER'S DISEASE DELAYS TIME TO NURSING HOME PLACEMENT
    Wattmo, Carina
    Londos, Elisabet
    Minthon, Lennart
    NEUROBIOLOGY OF AGING, 2016, 39 : S2 - S2
  • [36] CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients
    Clarelli, Ferdinando
    Mascia, Elisabetta
    Santangelo, Roberto
    Mazzeo, Salvatore
    Giacalone, Giacomo
    Galimberti, Daniela
    Fusco, Federica
    Zuffi, Marta
    Fenoglio, Chiara
    Franceschi, Massimo
    Scarpini, Elio
    Forloni, Gianluigi
    Magnani, Giuseppe
    Comi, Giancarlo
    Albani, Diego
    Boneschi, Filippo Martinelli
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 52 (04) : 1203 - 1208
  • [37] Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease
    Baakman, Anne Catrien
    Gavan, Carmen
    van Doeselaar, Lotte
    de Kam, Marieke
    Broekhuizen, Karen
    Bajenaru, Ovidiu
    Camps, Laura
    Swart, Eleonora L.
    Kalisvaart, Kees
    Schoonenboom, Niki
    Lemstra, Evelien
    Scheltens, Philip
    Cohen, Adam
    van Gerven, Joop
    Groeneveld, Geert Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (06) : 2814 - 2829
  • [38] Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease
    Xiaoli Pan
    Zhichun Chen
    Guoqiang Fei
    Shumei Pan
    Weiqi Bao
    Shuhua Ren
    Yihui Guan
    Chunjiu Zhong
    Neuroscience Bulletin, 2016, 32 (06) : 591 - 596
  • [39] Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for β-amyloid plasma levels?
    Sobow, Tomasz
    Kloszewska, Iwona
    Flirski, Marcin
    Liberski, Pawel
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2009, 43 (06) : 507 - 516
  • [40] Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
    Wallin, Asa K.
    Wattmo, Carina
    Minthon, Lennart
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 565 - 576